On Sept. 1, 2021, Rigel Pharma announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America. The study was sponsored by the National Heart, Lung, and Blood Institute.